Advancements in the application of direct thrombin inhibitors in cardiopulmonary bypass anticoagulation therapy
Wang He
Liu Jinping
Abstract：Heparin is currently the standard drug for anticoagulation during cardiopulmonary bypass(CPB)in cardiac surgery,but its adverse reactions,such as heparin allergy or heparin-induced thrombocytopenia(HIT),have been increasingly concerned.Direct thrombin inhibitors(DTIs),which directly bind to thrombin without the aforementioned adverse reactions,are recommended for anticoagulation management during CPB in patients experiencing heparin/protamine adverse reactions and requiring emergency surgery.In recent years,there have been many clinical case reports of DTIs.This article will briefly review the anticoagulation mechanism of DTIs and the clinical application progress of several drugs,providing new insights for anticoagulation treatment during CPB.
Keywords：Direct thrombin inhibitorsCardiopulmonary bypassHeparin-induced thrombocytopeniaAnticoagulation
Publication Date：2024-06-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 242-245,256 )